These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 28736931)

  • 1. Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.
    Rotroff DM; Pijut SS; Marvel SW; Jack JR; Havener TM; Pujol A; Schluter A; Graf GA; Ginsberg HN; Shah HS; Gao H; Morieri ML; Doria A; Mychaleckyi JC; McLeod HL; Buse JB; Wagner MJ; Motsinger-Reif AA;
    Clin Pharmacol Ther; 2018 Apr; 103(4):712-721. PubMed ID: 28736931
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Morieri ML; Shah HS; Sjaarda J; Lenzini PA; Campbell H; Motsinger-Reif AA; Gao H; Lovato L; Prudente S; Pandolfi A; Pezzolesi MG; Sigal RJ; Paré G; Marcovina SM; Rotroff DM; Patorno E; Mercuri L; Trischitta V; Chew EY; Kraft P; Buse JB; Wagner MJ; Cresci S; Gerstein HC; Ginsberg HN; Mychaleckyj JC; Doria A
    Diabetes; 2020 Apr; 69(4):771-783. PubMed ID: 31974142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Summarizing the FIELD study: lessons from a 'negative' trial.
    Tsimihodimos V; Mikhailidis DP; Elisaf M
    Expert Opin Pharmacother; 2013 Dec; 14(18):2601-10. PubMed ID: 24206060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Perspectives of the use of fenofibrate in patients with type 2 diabetes mellitus: what is new after the ACCORD Study?].
    Susekov AV; Khokhlova NV
    Kardiologiia; 2011; 51(9):68-74. PubMed ID: 21943011
    [No Abstract]   [Full Text] [Related]  

  • 6. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
    Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
    JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
    Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; González-Santos P; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X;
    Clin Investig Arterioscler; 2016; 28(6):295-301. PubMed ID: 27609708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
    Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
    Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of fenofibrate on cardiometabolic risk factors in bromocriptine-treated women with mixed dyslipidemia: A pilot study.
    Krysiak R; Okrzesik J; Szkrobka W; Okopień B
    Pharmacol Rep; 2016 Feb; 68(1):185-9. PubMed ID: 26721371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia.
    Ghani RA; Bin Yaakob I; Wahab NA; Zainudin S; Mustafa N; Sukor N; Wan Mohamud WN; Kadir KA; Kamaruddin NA
    J Clin Lipidol; 2013; 7(5):446-53. PubMed ID: 24079286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fenofibrate attenuates diabetic nephropathy in experimental diabetic rat's model via suppression of augmented TGF-β1/Smad3 signaling pathway.
    Al-Rasheed NM; Al-Rasheed NM; Al-Amin MA; Hasan IH; Al-Ajmi HN; Mohammad RA; Attia HA
    Arch Physiol Biochem; 2016 Oct; 122(4):186-194. PubMed ID: 26959841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of fenofibrate in clinical practice.
    Zambon A; Cusi K
    Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
    Kei A; Tellis C; Liberopoulos E; Tselepis A; Elisaf M
    Cardiovasc Ther; 2014 Aug; 32(4):139-46. PubMed ID: 24618208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significant association between rare IPO11-HTR1A variants and attention deficit hyperactivity disorder in Caucasians.
    Zuo L; Saba L; Lin X; Tan Y; Wang K; Krystal JH; Tabakoff B; Luo X
    Am J Med Genet B Neuropsychiatr Genet; 2015 Oct; 168(7):544-56. PubMed ID: 26079129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of simvastatin and fenofibrate on the expression of leukocyte adhesion molecules and lipopolysaccharide receptor CD14 in type 2 diabetes mellitus.
    Stulc T; Ceska R; Marinov I; Skrha J
    Neuro Endocrinol Lett; 2012; 33 Suppl 2():73-7. PubMed ID: 23183514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of fenofibrate as an add-on in patients with elevated triglyceride despite receiving statin treatment.
    Zhao S; Wang F; Dai Y; Lin L; Tong Q; Liao Y; Yin Y; Wang G; Yan Y; Li X; Wang D; Wei P; Cheng X; Xie Q; Sun Y; Fu G; Huang H; Dong Y; Liu J; Yan J; Yan L; Cui S; Liu X; Li Z; Chen H; Hu T; Gong H
    Int J Cardiol; 2016 Oct; 221():832-6. PubMed ID: 27434354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?
    Steiner G
    Treat Endocrinol; 2005; 4(5):311-7. PubMed ID: 16185099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia.
    Pruski M; Krysiak R; Okopien B
    Diabetes Care; 2009 Aug; 32(8):1421-4. PubMed ID: 19435959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial.
    Tsunoda F; Asztalos IB; Horvath KV; Steiner G; Schaefer EJ; Asztalos BF
    Atherosclerosis; 2016 Apr; 247():35-39. PubMed ID: 26854974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.